Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics (MRKR – Research Report), with a price target of $8.00.

John Newman’s rating is based on the promising developments in Marker Therapeutics’ MT-601 treatment, particularly in the APOLLO study. The use of lymphodepletion has shown to significantly enhance the expansion of MT-601, which is expected to lead to improved efficacy results by late 2025. The recent data indicates that incorporating lymphodepletion into the treatment protocol for all patients could bolster the treatment’s effectiveness.
Additionally, the acceleration of patient enrollment in the APOLLO study further supports the potential for robust data outcomes. With the expectation of more patients and enhanced efficacy in upcoming updates, the initial results have already demonstrated a notable overall response rate and complete remission rate in B-cell lymphoma patients. These factors contribute to the confidence in maintaining a Buy rating with a price target of $8 for MRKR.

MRKR’s price has also changed dramatically for the past six months – from $3.180 to $1.140, which is a -64.15% drop .